Angiosarcomas are a heterogeneous group of rare endothelial
malignancies with a complex, not completely unravelled biology. They encompass primary (sporadically occurring)
angiosarcomas of several origins and secondary
angiosarcomas, which often arise due to
DNA damaging factors including
radiotherapy or ultraviolet light exposure. The optimal treatment of metastatic
angiosarcomas is unclear and the prognosis is poor. In order to discover novel treatment strategies for
angiosarcomas it is important to take the heterogeneity of these
tumors into account. For this reason it is also important to have preclinical models available for the different clinical subtypes. Owing to the rarity of
angiosarcomas, models are scarce. So far, only five human cell lines of
angiosarcomas (all of the scalp after UV exposure) are available worldwide. In this paper we describe a novel established patient-derived xenograft model of a
radiotherapy-induced
angiosarcoma of the breast. The
tumor was characterized by a MYC amplification, CD31 and ERG immunohistochemical positivity and was further characterized by using next generation sequencing (TruSight Oncology 500) in combination with the R-package XenofilteR to separate mouse from human sequence reads.